A series of novel compounds carrying pyrazino[1,2-a]indol-1(2H)-one scaffold (5a-g) and their reaction intermediates, indole-2-carboxamides, (3a-g) were synthesized and evaluated for their ability to inhibit reactive oxygen species (ROS) generation, antioxidant activity and anticancer activity against a panel of cancer cell lines using MTT assay. The results showed that these compounds can inhibit ROS generation during the metabolic phase of phagocytosis in a dose-dependent manner where compounds 5d and 5e were the most potent samples with higher inhibitory activities (IC50 values 3.3 and 1.4 µM, respectively) than that of the reference acetylsalicylic acid (IC50 ¼ 9.7 µM). Results for the determination of potential antioxidant properties of the synthesized compounds showed that compounds 5d and 5e containing pyrazino[1,2-a]indol-1-one backbone were the most acive and even comparable to Trolox. Compounds 3d-f and 5d-f with the least IC50 values in MTT assay were tested against three known anticancer targets EGFR, BRAF and Tubulin. Histopathological and immunohistochemical study were performed to determine the consequence of exposure to chronic low dose of chlorpyrifos on the testis of male mice and results revealed that these effects can be ameliorated by co-treatment with the most active antioxidant compounds 5d and 5e. Finally, molecular docking studies were performed to explore the binding mode of the most active compounds against EGFR and BRAF kinases.

Three new series of 5-aminosalicylic acid derivatives; series I (14, 16–18), series II (19–30) and series III (31–41) were synthesized as potential dual COX-2/5-LOX inhibitors. Their chemical structures were confirmed using spectroscopic tools including IR, 1H NMR, 13C NMR, mass spectroscopy and elemental analyses. The anti-inflammatory activity for all target compounds was evaluated in vivo using carrageenan-induced paw edema. Compound 36 showed the highest anti-inflammatory activity (114.12%) relative to reference drug indomethacin at 4 h interval. Selected derivatives were evaluated in vitro to inhibit ovine COX-1, human recombinant COX-2 and 5-LOX enzymes. Compounds 34 & 35 exhibited significant COX-2 inhibition (IC50 = 0.10 µM) with significant COX-2 selectivity indices (SI = 135 & 145 respectively) approximate to celecoxib (IC50 = 0.049 µM, SI = 308.16) and exceeding indomethacin (IC50 = 0.51 µM, SI = 0.08). Interestingly, all compounds showed superior 5-LOX inhibitory activity about 2–5 times relative to zileuton. Compound 16 was the superlative 5-LOX inhibitor that revealed (IC50 = 3.41 µM) relative to zileuton (IC50 = 15.6 µM). Compounds 34, 35, 36 and 41 showed significant dual COX-2/5-LOX inhibitions. The gastric ulcerogenic effect of compound 36 was examined on gastric mucosa of albino rats and they showed superior GI safety profile compared with indomethacin. Molecular docking studies of the compounds into the binding sites of COX-1, COX-2 and 5-LOX allowed us to shed light on the binding mode of these novels dual COX and 5-LOX inhibitors.

Three new series of 5-aminosalicylic acid derivatives; series I (14, 16–18), series II (19–30) and series III (31–41) were synthesized as potential dual COX-2/5-LOX inhibitors. Their chemical structures were confirmed using spectroscopic tools including IR, 1H NMR, 13C NMR, mass spectroscopy and elemental analyses. The anti-inflammatory activity for all target compounds was evaluated in vivo using carrageenan-induced paw edema. Compound 36 showed the highest anti-inflammatory activity (114.12%) relative to reference drug indomethacin at 4 h interval. Selected derivatives were evaluated in vitro to inhibit ovine COX-1, human recombinant COX-2 and 5-LOX enzymes. Compounds 34 & 35 exhibited significant COX-2 inhibition (IC50 = 0.10 µM) with significant COX-2 selectivity indices (SI = 135 & 145 respectively) approximate to celecoxib (IC50 = 0.049 µM, SI = 308.16) and exceeding indomethacin (IC50 = 0.51 µM, SI = 0.08). Interestingly, all compounds showed superior 5-LOX inhibitory activity about 2–5 times relative to zileuton. Compound 16 was the superlative 5-LOX inhibitor that revealed (IC50 = 3.41 µM) relative to zileuton (IC50 = 15.6 µM). Compounds 34, 35, 36 and 41 showed significant dual COX-2/5-LOX inhibitions. The gastric ulcerogenic effect of compound 36 was examined on gastric mucosa of albino rats and they showed superior GI safety profile compared with indomethacin. Molecular docking studies of the compounds into the binding sites of COX-1, COX-2 and 5-LOX allowed us to shed light on the binding mode of these novels dual COX and 5-LOX inhibitors.

Three new series of 5-aminosalicylic acid derivatives; series I (14, 16–18), series II (19–30) and series III (31–41) were synthesized as potential dual COX-2/5-LOX inhibitors. Their chemical structures were confirmed using spectroscopic tools including IR, 1H NMR, 13C NMR, mass spectroscopy and elemental analyses. The anti-inflammatory activity for all target compounds was evaluated in vivo using carrageenan-induced paw edema. Compound 36 showed the highest anti-inflammatory activity (114.12%) relative to reference drug indomethacin at 4 h interval. Selected derivatives were evaluated in vitro to inhibit ovine COX-1, human recombinant COX-2 and 5-LOX enzymes. Compounds 34 & 35 exhibited significant COX-2 inhibition (IC50 = 0.10 µM) with significant COX-2 selectivity indices (SI = 135 & 145 respectively) approximate to celecoxib (IC50 = 0.049 µM, SI = 308.16) and exceeding indomethacin (IC50 = 0.51 µM, SI = 0.08). Interestingly, all compounds showed superior 5-LOX inhibitory activity about 2–5 times relative to zileuton. Compound 16 was the superlative 5-LOX inhibitor that revealed (IC50 = 3.41 µM) relative to zileuton (IC50 = 15.6 µM). Compounds 34, 35, 36 and 41 showed significant dual COX-2/5-LOX inhibitions. The gastric ulcerogenic effect of compound 36 was examined on gastric mucosa of albino rats and they showed superior GI safety profile compared with indomethacin. Molecular docking studies of the compounds into the binding sites of COX-1, COX-2 and 5-LOX allowed us to shed light on the binding mode of these novels dual COX and 5-LOX inhibitors.

Three new series of 5-aminosalicylic acid derivatives; series I (14, 16–18), series II (19–30) and series III (31–41) were synthesized as potential dual COX-2/5-LOX inhibitors. Their chemical structures were confirmed using spectroscopic tools including IR, 1H NMR, 13C NMR, mass spectroscopy and elemental analyses. The anti-inflammatory activity for all target compounds was evaluated in vivo using carrageenan-induced paw edema. Compound 36 showed the highest anti-inflammatory activity (114.12%) relative to reference drug indomethacin at 4 h interval. Selected derivatives were evaluated in vitro to inhibit ovine COX-1, human recombinant COX-2 and 5-LOX enzymes. Compounds 34 & 35 exhibited significant COX-2 inhibition (IC50 = 0.10 µM) with significant COX-2 selectivity indices (SI = 135 & 145 respectively) approximate to celecoxib (IC50 = 0.049 µM, SI = 308.16) and exceeding indomethacin (IC50 = 0.51 µM, SI = 0.08). Interestingly, all compounds showed superior 5-LOX inhibitory activity about 2–5 times relative to zileuton. Compound 16 was the superlative 5-LOX inhibitor that revealed (IC50 = 3.41 µM) relative to zileuton (IC50 = 15.6 µM). Compounds 34, 35, 36 and 41 showed significant dual COX-2/5-LOX inhibitions. The gastric ulcerogenic effect of compound 36 was examined on gastric mucosa of albino rats and they showed superior GI safety profile compared with indomethacin. Molecular docking studies of the compounds into the binding sites of COX-1, COX-2 and 5-LOX allowed us to shed light on the binding mode of these novels dual COX and 5-LOX inhibitors.

Three new series of 5-aminosalicylic acid derivatives; series I (14, 16–18), series II (19–30) and series III (31–41) were synthesized as potential dual COX-2/5-LOX inhibitors. Their chemical structures were confirmed using spectroscopic tools including IR, 1H NMR, 13C NMR, mass spectroscopy and elemental analyses. The anti-inflammatory activity for all target compounds was evaluated in vivo using carrageenan-induced paw edema. Compound 36 showed the highest anti-inflammatory activity (114.12%) relative to reference drug indomethacin at 4 h interval. Selected derivatives were evaluated in vitro to inhibit ovine COX-1, human recombinant COX-2 and 5-LOX enzymes. Compounds 34 & 35 exhibited significant COX-2 inhibition (IC50 = 0.10 µM) with significant COX-2 selectivity indices (SI = 135 & 145 respectively) approximate to celecoxib (IC50 = 0.049 µM, SI = 308.16) and exceeding indomethacin (IC50 = 0.51 µM, SI = 0.08). Interestingly, all compounds showed superior 5-LOX inhibitory activity about 2–5 times relative to zileuton. Compound 16 was the superlative 5-LOX inhibitor that revealed (IC50 = 3.41 µM) relative to zileuton (IC50 = 15.6 µM). Compounds 34, 35, 36 and 41 showed significant dual COX-2/5-LOX inhibitions. The gastric ulcerogenic effect of compound 36 was examined on gastric mucosa of albino rats and they showed superior GI safety profile compared with indomethacin. Molecular docking studies of the compounds into the binding sites of COX-1, COX-2 and 5-LOX allowed us to shed light on the binding mode of these novels dual COX and 5-LOX inhibitors.

Polymeric nanoparticles (NPs) are decorated with various types of molecules to control their functions and interactions with specific cells. We previously used polydopamine (pD) to prime-coat poly(lactic-co-glycolic acid) (PLGA) NPs and conjugated functional ligands onto the NPs via the pD coating. In this study, we report tannic acid (TA) as an alternative prime coating that is functionally comparable to pD but does not have drawbacks of pD such as optical properties and interference of ligand characterization. TA forms a stable and optically inert coating on PLGA NPs, which can accommodate albumin, chitosan, and folate-terminated polyethylene glycol to control the cell-NP interactions. Moreover, TA coating allows for surface loading of polycyclic planar aromatic compounds. TA is a promising reactive intermediate for surface functionalization of polymeric NPs.

Purpose: To develop a safe, lipid-based non-viral gene delivery system that achieves high transfection efficiency in the presence of serum proteins. Methods: Polyplexes with the pAcGFP1-C1 plasmid were formed in phosphate buffered saline, pH 7.4 (PBS) using the novel poly[N-(2-hydroxypropyl)methacrylamide]-poly(N,N-dimethylaminoethylmethacrylate) diblock copolymer (pHPMA-b-pDMAEMA) at N/P=4. Cationic-Liposomes were prepared from a dried lipid film comprised of equimolar 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) and 1,2-dioleoyl-sn-glycero-3- phosphoethanolamine (DOPE). Lipopolyplexes were fabricated at lipid/DNA weight ratios up to 40. Particle size distribution and zeta potential of lipopolyplexes were determined by dynamic light scattering. HeLa cells viability in the presence and absence of lipopolyplexes was quantified using the CellTiter-Glo® luminescent assay. HeLa cell transfection efficiency in the presence and absence of FBS was visually assessed by confocal microscopy and quantitatively compared to the TurboFect™ control. Results: pHPMA-b-pDMAEMA exhibited a high condensation capacity of 1 μg of pDNA per 0.513 μg of polymer (N/P=1). Lipid-coating of polyplexes at lipid/DNA weight ratios up to 40 resulted in particle sizes +25 mV. Exposure to FBS significantly increased mean particle size to >300 nm, reduced zeta potential to -10 mV, and augmented polydispersity. Lipid coating of polyplexes only decreased HeLa cell viability at lipid/DNA ratios >20. HeLa transfection with lipopolyplexes was most effective at lipid/DNA = 20 and was significantly greater in the presence of FBS than measured for lipid-free polyplexes. Conclusion: Lipid coating of pHPMA-b-pDMAEMA/DNA polyplexes with an equimolar DOTAP/DOPE mixture at a lipid/DNA ratio = 20 effectively enhances in vitro transfection efficiency of HeLa cells in the presence of serum proteins.

Purpose: To develop a safe, lipid-based non-viral gene delivery system that achieves high transfection efficiency in the presence of serum proteins. Methods: Polyplexes with the pAcGFP1-C1 plasmid were formed in phosphate buffered saline, pH 7.4 (PBS) using the novel poly[N-(2-hydroxypropyl)methacrylamide]-poly(N,N-dimethylaminoethylmethacrylate) diblock copolymer (pHPMA-b-pDMAEMA) at N/P=4. Cationic-Liposomes were prepared from a dried lipid film comprised of equimolar 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) and 1,2-dioleoyl-sn-glycero-3- phosphoethanolamine (DOPE). Lipopolyplexes were fabricated at lipid/DNA weight ratios up to 40. Particle size distribution and zeta potential of lipopolyplexes were determined by dynamic light scattering. HeLa cells viability in the presence and absence of lipopolyplexes was quantified using the CellTiter-Glo® luminescent assay. HeLa cell transfection efficiency in the presence and absence of FBS was visually assessed by confocal microscopy and quantitatively compared to the TurboFect™ control. Results: pHPMA-b-pDMAEMA exhibited a high condensation capacity of 1 μg of pDNA per 0.513 μg of polymer (N/P=1). Lipid-coating of polyplexes at lipid/DNA weight ratios up to 40 resulted in particle sizes +25 mV. Exposure to FBS significantly increased mean particle size to >300 nm, reduced zeta potential to -10 mV, and augmented polydispersity. Lipid coating of polyplexes only decreased HeLa cell viability at lipid/DNA ratios >20. HeLa transfection with lipopolyplexes was most effective at lipid/DNA = 20 and was significantly greater in the presence of FBS than measured for lipid-free polyplexes. Conclusion: Lipid coating of pHPMA-b-pDMAEMA/DNA polyplexes with an equimolar DOTAP/DOPE mixture at a lipid/DNA ratio = 20 effectively enhances in vitro transfection efficiency of HeLa cells in the presence of serum proteins.

Purpose: To develop a safe, lipid-based non-viral gene delivery system that achieves high transfection efficiency in the presence of serum proteins. Methods: Polyplexes with the pAcGFP1-C1 plasmid were formed in phosphate buffered saline, pH 7.4 (PBS) using the novel poly[N-(2-hydroxypropyl)methacrylamide]-poly(N,N-dimethylaminoethylmethacrylate) diblock copolymer (pHPMA-b-pDMAEMA) at N/P=4. Cationic-Liposomes were prepared from a dried lipid film comprised of equimolar 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) and 1,2-dioleoyl-sn-glycero-3- phosphoethanolamine (DOPE). Lipopolyplexes were fabricated at lipid/DNA weight ratios up to 40. Particle size distribution and zeta potential of lipopolyplexes were determined by dynamic light scattering. HeLa cells viability in the presence and absence of lipopolyplexes was quantified using the CellTiter-Glo® luminescent assay. HeLa cell transfection efficiency in the presence and absence of FBS was visually assessed by confocal microscopy and quantitatively compared to the TurboFect™ control. Results: pHPMA-b-pDMAEMA exhibited a high condensation capacity of 1 μg of pDNA per 0.513 μg of polymer (N/P=1). Lipid-coating of polyplexes at lipid/DNA weight ratios up to 40 resulted in particle sizes +25 mV. Exposure to FBS significantly increased mean particle size to >300 nm, reduced zeta potential to -10 mV, and augmented polydispersity. Lipid coating of polyplexes only decreased HeLa cell viability at lipid/DNA ratios >20. HeLa transfection with lipopolyplexes was most effective at lipid/DNA = 20 and was significantly greater in the presence of FBS than measured for lipid-free polyplexes. Conclusion: Lipid coating of pHPMA-b-pDMAEMA/DNA polyplexes with an equimolar DOTAP/DOPE mixture at a lipid/DNA ratio = 20 effectively enhances in vitro transfection efficiency of HeLa cells in the presence of serum proteins.